Overview

• Lenacapavir, marketed as Yeztugo by Gilead Sciences, proved 99.9% effective in clinical trials with just two subcutaneous injections per year.
• Gilead set a U.S. list price of $28,218 annually, far above the $25 per-person production estimate by independent researchers.
• The company licensed six generic manufacturers to supply low-cost versions in 120 low-income countries and will provide 2 million doses at no profit until generics launch.
• Recent cuts to funding programs including PEPFAR and the Global Fund have cast doubt on financing for widespread distribution in resource-limited regions.
• Health experts and UNAIDS warn that without affordable pricing and reliable funding, the injection’s global impact on ending HIV transmission could be undermined.